Human Chronic Lymphoid Leukemia PB CD19+/CD5+ B Cells (Relapsed/Refractory)

Description

Human Chronic Lymphoid Leukemia PB CD19+/CD5+ B Cells (Relapsed/Refractory) are primary lymphoid cells isolated from the peripheral blood of patients diagnosed with relapsed or refractory chronic lymphocytic leukemia (CLL). Morphologically, the cells are small to medium-sized with clumped chromatin and scant cytoplasm, and exhibit a non-adherent, suspension growth pattern in vitro. Chromosomal abnormalities such as del(17p), TP53 mutations, or del(11q) are frequently observed in relapsed/refractory CLL and contribute to therapeutic resistance. These primary B cells are cryopreserved post-isolation and typically non-proliferative under standard culture conditions. Immunophenotyping confirms expression of CD19, CD5, and CD23 using multicolor flow cytometry. The unique co-expression of CD19 and CD5 plays a role in aberrant signal transduction and disease persistence. Each lot undergoes rigorous screening and isolation procedures, and is rigorously tested to ensure it is free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.